Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

February 2021

New Scientific Publications Show Diadem's Blood-Based AlzoSure® Biomarker Test Can Predict Which Patients Will Progress to Alzheimer's Disease Years Before Symptoms Occur

Diadem, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the publication of three new scientific studies that support the utility of its biomarker assay to identify individuals at high risk for AD. The publications describe the role of a conformational variant of the p53 protein ( U-p53AZ) in the pathogenesis of AD, as well as its applicability as a predictive biomarker to identify individuals likely to progress to AD up to six years before symptoms appear.

Two of the papers report the results of early studies that confirm the accuracy of the U-p53AZ-based assay, in development by Diadem as AlzoSure® Predict, as a prognostic test for AD.
Diadem is developing the AlzoSure assay as a simple, non-invasive plasma-based biomarker test to accurately predict the probability that a patient with asymptomatic mild cognitive impairment (MCI) will progress to Alzheimer’s dementia. 
 


The company’s patented technology uses an analytical method that includes a proprietary antibody designed to bind to U-p53AZ and target sequences developed by Diadem.
 

Further clinical studies of the assay are underway, and the company plans a global launch in collaboration with strategic partners later this year.
 
Paul Kinnon
CEO @ Diadem

 

Together, these studies highlight why we are so excited about the potential of AlzoSure to have a major impact on this devastating disease. They describe how this conformational variant of p53 contributes to the ongoing pathology of AD, as well as how its role in disease progression makes it useful as a biomarker to identify patients whose neurons are already under attack. The simplicity and affordability of our blood-based biomarker test mean that it will be available to individuals in primary care settings, which will make widespread screening feasible. This is turn will help spur the development of new drugs for AD, which now will be able to be widely administered early in the disease process, when the chances for slowing and stopping the cognitive ravages of AD are the greatest.

 

Leggi l'articolo completo
act

News

Scopri la sezione News per restare sempre aggiornato su ciò che riguarda gli zoner e sui temi pià rilevanti legati all'innovazione e alle Scienze della Vita.
tutte le news